Please login to the form below
anaesthetics
This page shows the latest anaesthetics news and features for those working in and with pharma, biotech and healthcare.
Acacia finally gets FDA okay for first product Barhemsys
Meanwhile, the UK company is also preparing for a possible approval by 5 April of ByFavo (remimazolam), an ultra-short-acting and reversible intravenous benzodiazepine sedative/anaesthetic for use during procedural
Latest news
-
Sandoz expands into Japan with €400m Aspen deal
Aspen’s portfolio consists of approximately 20 off-patent medicines, including anaesthetics like Xylocaine and speciality brands such as immune suppressing drug Imuran for multiple sclerosis patients.
-
Stung by critics, J&J says antidepressant Spravato saves money
It is a single isomer form of ketamine, a low-cost anaesthetic, and ICER says the similarity between the two drugs “raises issues for all stakeholders about how to consider
-
J&J’s Spravato breaks depression drought at FDA
The green light for nasal spray formulation of esketamine – a derivative of the anaesthetic ketamine – is for use of the drug as an add-on to oral antidepressants in people with
-
Gyroscope's gene therapy given to first dry AMD patient
GT005 was administered under a local anaesthetic by Robert MacLaren, an ophthalmology specialist at Oxford Eye Hospital.
-
FDA panel backs J&J’s new-class antidepressant
The nasal spray formulation of esketamine – a derivative of the anaesthetic ketamine that has the proposed name Spravato – was backed by a 14-2 vote by an FDA advisory committee yesterday
More from news
Approximately 1 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2016
200+. Janssen / J&J (US). Piramal (IN). Asset acquisition. 5 injectable pain / anaesthetic products.
-
Deal Watch September 2016
500. GSK / Aspen. Asset acquisition. Sale of anaesthetic drugs [Ultiva, Nimbex, Tracrium, Mivacron and Anectinein – excludes US/CA rights].
-
Deal Watch June 2016
Meanwhile AstraZeneca has out-licensed ex-US rights to a portfolio of seven anaesthetics to Aspen. ... Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and
-
Pharma deals in June 2015
Neosaxitoxin, novel anaesthetic for local anaesthesia and post-op pain management. Collaboration, licence.
-
Pharma deals during March 2014
Baxter's medical products business has annual sales of over $9bn and a portfolio of intravenous solutions and nutritional therapies, drug delivery systems, premixed and other injectable drugs, inhalation anaesthetics and
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Addressing Climate Impact: The Healthcare Paradox
Similarly, some procedures are particularly carbon intensive. Hospitals have been exploring solutions ranging from retrofitting heat recovery technology to dialysis machines, to switching operating room anaesthetics, which account for almost a
-
It’s all about patient outcomes… right?
general anaesthetic. ... Routledge; London, UK, 2002. Snow SJ. Blessed Days of Anaesthesia: How Anaesthetics Changed the World.
-
"Legal highs" ruling leaves illegal labs laughing
These include the anaesthetic nitrous oxide, or laughing gas. . N2O has been used as a recreational drug since 1799, when 'laughing gas parties' were popular among the ruling classes.
-
Healthcare 2025: what the future holds for pharma
This was led by major advances in three core areas:. Health: Access to innovative medicines, surgery and anaesthetics, clean air and water.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Amgen adds Otezla to the COVID-19 candidate list
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July
- Impetus Digital Fireside Chat with Susanne Somerville of Chronicled
- Impetus Digital Fireside Chat with Bechara Saab of Mobio Interactive
- FDA delays review of Novartis’ MS drug ofatumumab
- Sanofi makes ‘best-in-class’ claim for Sarclisa in myeloma
- Q&A: Kay Wesley
PMHub
Syneos Health™
Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
